213 related articles for article (PubMed ID: 21658788)
1. Tissue sampling in lung cancer: a review in light of the MERIT experience.
Reck M; Hermes A; Tan EH; Felip E; Klughammer B; Baselga J
Lung Cancer; 2011 Oct; 74(1):1-6. PubMed ID: 21658788
[TBL] [Abstract][Full Text] [Related]
2. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
[TBL] [Abstract][Full Text] [Related]
3. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Sequist LV; Bell DW; Lynch TJ; Haber DA
J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
[TBL] [Abstract][Full Text] [Related]
4. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
8. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A
Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561
[TBL] [Abstract][Full Text] [Related]
9. Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC.
Rogers SJ; Harrington KJ; Eccles SA; Nutting CM
Expert Rev Anticancer Ther; 2004 Aug; 4(4):569-83. PubMed ID: 15270661
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
11. Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer.
Cadranel J; Zalcman G; Sequist L
Eur Respir J; 2011 Jan; 37(1):183-93. PubMed ID: 21030453
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
13. Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges.
Langer CJ
Crit Rev Oncol Hematol; 2012 Jul; 83(1):130-44. PubMed ID: 22280915
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
Santarpia M; Altavilla G; Salazar MF; Magri I; Pettineo G; Benecchi S; Rosell R
Expert Rev Respir Med; 2011 Jun; 5(3):413-24. PubMed ID: 21702662
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
Eberhard DA; Giaccone G; Johnson BE;
J Clin Oncol; 2008 Feb; 26(6):983-94. PubMed ID: 18281673
[TBL] [Abstract][Full Text] [Related]
16. Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
Laack E; Sauter G; Bokemeyer C
Lung Cancer; 2010 Sep; 69(3):259-64. PubMed ID: 20646778
[TBL] [Abstract][Full Text] [Related]
17. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers for EGFR therapy.
Sakurada A; Tsao MS
IDrugs; 2009 Jan; 12(1):34-8. PubMed ID: 19127503
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
Giaccone G; Gallegos Ruiz M; Le Chevalier T; Thatcher N; Smit E; Rodriguez JA; Janne P; Oulid-Aissa D; Soria JC
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6049-55. PubMed ID: 17062680
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]